Changes in Hong Kong stocks | Cinda Biotech (01801) is now down more than 4%, and the company has completed the placement of a total of 55 million shares. Institutions are still optimistic about the subsequent commercialization of Mashidu Peptide

The Zhitong Finance App learned that Cinda Biotech (01801) is now down more than 4%. As of press release, it is down 3.94% to HK$82.8, with a turnover of HK$993 million.

According to the news, Cinda Biotech announced that it has successfully distributed a total of 55 million shares. The company previously announced that it plans to sell 55 million shares at a discount of about 4.9%, with an estimated net proceeds of about HK$4.265 billion. It plans to use about 90% to promote the global research and development of the company's rich clinical and pre-clinical key innovation pipelines, as well as the company's global facility and equipment layout; about 10% will be used for the company's daily operations.

CITIC Construction Investment released a research report stating that Cinda BioMashidu Peptide was approved for listing on June 27, and subsequent commercialization is imminent. In the previous phase III weight loss study, Mashidu peptide showed excellent weight loss effects. After 32 weeks of placebo correction, it also significantly reduced indicators such as liver fat, blood pressure, blood lipids, and blood uric acid, bringing comprehensive benefits to obese people. As the product is soon to be commercialized, many obese people are expected to benefit from Mashidol peptides.